Current outlook on radionuclide delivery systems: from design consideration to translation into clinics

Peltek, Oleksii O.; Muslimov, Аlbert R.; Zyuzin, Mikhail V.; Timin, Alexander S.

doi:10.1186/s12951-019-0524-9

Cited by 66 publications

(44 citation statements)

References 245 publications

(272 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the future, activated gold might be considered as a radionuclide for isotope scanning, a method of clinical diagnosis that has been used for decades [ 53 ], and, for that purpose, the scanning sensor needs to be adjusted to the necessary energy of gamma rays emitted by activated gold. Thus, the development of the proposed BNCT dosimetry approach might also provide detection of tumor localization by building composite images of boron- and gold-saturated tumor cells, leading to further utilization of this method in isotope scanning after its appropriate modification for BNCT needs.…”

Section: Discussionmentioning

confidence: 99%

Gold Nanoparticles Permit In Situ Absorbed Dose Evaluation in Boron Neutron Capture Therapy for Malignant Tumors

et al. 2021

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is an anticancer modality realized through 10B accumulation in tumor cells, neutron irradiation of the tumor, and decay of boron atoms with the release of alpha-particles and lithium nuclei that damage tumor cell DNA. As high-LET particle release takes place inside tumor cells absorbed dose calculations are difficult, since no essential extracellular energy is emitted. We placed gold nanoparticles inside tumor cells saturated with boron to more accurately measure the absorbed dose. T98G cells accumulated ~50 nm gold nanoparticles (AuNPs, 50 µg gold/mL) and boron-phenylalanine (BPA, 10, 20, 40 µg boron-10/mL), and were irradiated with a neutron flux of 3 × 108 cm−2s−1. Gamma-rays (411 keV) emitted by AuNPs in the cells were measured by a spectrometer and the absorbed dose was calculated using the formula D = (k × N × n)/m, where D was the absorbed dose (GyE), k—depth-related irradiation coefficient, N—number of activated gold atoms, n—boron concentration (ppm), and m—the mass of gold (g). Cell survival curves were fit to the linear-quadratic (LQ) model. We found no influence from the presence of the AuNPs on BNCT efficiency. Our approach will lead to further development of combined boron and high-Z element-containing compounds, and to further adaptation of isotope scanning for BNCT dosimetry.

show abstract

Section: Discussionmentioning

confidence: 99%

Gold Nanoparticles Permit In Situ Absorbed Dose Evaluation in Boron Neutron Capture Therapy for Malignant Tumors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Nanoparticles can be used to encapsule radionuclide such as I125 via electrophilic aromatic substitution which is in high radiochemical yields. Through this straightforward way, radionuclide can be stored in the stable core [ 47 , 48 ]. Dey [ 49 ] developed a self-assembling peptide/protein nanoparticle with the size only 11 nm in diameter and it exhibited good biocompatibility and stability in vivo, indicating it should be suitable for drug delivery in cancer treatment.…”

Section: Nanomaterials Used For Cancer Treatmentmentioning

confidence: 99%

Nanomaterials for cancer therapy: current progress and perspectives

et al. 2021

View full text Add to dashboard Cite

Cancer is a disease with complex pathological process. Current chemotherapy faces problems such as lack of specificity, cytotoxicity, induction of multi-drug resistance and stem-like cells growth. Nanomaterials are materials in the nanorange 1–100 nm which possess unique optical, magnetic, and electrical properties. Nanomaterials used in cancer therapy can be classified into several main categories. Targeting cancer cells, tumor microenvironment, and immune system, these nanomaterials have been modified for a wide range of cancer therapies to overcome toxicity and lack of specificity, enhance drug capacity as well as bioavailability. Although the number of studies has been increasing, the number of approved nano-drugs has not increased much over the years. To better improve clinical translation, further research is needed for targeted drug delivery by nano-carriers to reduce toxicity, enhance permeability and retention effects, and minimize the shielding effect of protein corona. This review summarizes novel nanomaterials fabricated in research and clinical use, discusses current limitations and obstacles that hinder the translation from research to clinical use, and provides suggestions for more efficient adoption of nanomaterials in cancer therapy.

show abstract

“…MNP selection is dependent upon the intended in vivo pharmacokinetics in order to attain desirable targeting efficiency with minimal toxicity. Gold nanoparticles (AuNPs) (Hu et al, 2006; Shukla et al, 2005; Yeh, Creran, & Rotello, 2012) and iron oxide nanoparticles (IONPs) (Morales‐Avila et al, 2011; Peltek, Muslimov, Zyuzin, & Timin, 2019) are extensively employed as core‐particles for incorporating/attaching radionuclides in radiotherapy (RT) and nano‐diagnostics due to their low toxicity, superior biocompatibility, and ease of functionalization, as well as MRI capabilities of IONPs. Other MNPs have also been reported, including Ag, Gd 2 O 3 , TiO 2 , Co, Ce, CeO 2 , Mn 3 O 4 , and ZrO 2 among many others.…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

“…Radiochemical doping refers to a direct radiolabeling process that the radionuclide is incorporated into its cold counterpart or surrogate of the reagents for the synthesis of MNPs, which results in intrinsically radioactive MNPs with high radiolabeling yield and stability (Goel et al, 2014; Peltek et al, 2019; Z. Zhang, 2016). Although this method forms highly stable radioactive MNPs, the increased radiation exposure during their production is a significant working hazard (X.…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Bahadori

Mulgaonkar

Hart

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Radiolabeled metal‐based nanoparticles (MNPs) have drawn considerable attention in the fields of nuclear medicine and molecular imaging, drug delivery, and radiation therapy, given the fact that they can be potentially used as diagnostic imaging and/or therapeutic agents, or even as theranostic combinations. Here, we present a systematic review on recent advances in the design and synthesis of MNPs with major focuses on their radiolabeling strategies and the determinants of their in vivo pharmacokinetics, and together how their intended applications would be impacted. For clarification, we categorize all reported radiolabeling strategies for MNPs into indirect and direct approaches. While indirect labeling simply refers to the use of bifunctional chelators or prosthetic groups conjugated to MNPs for post‐synthesis labeling with radionuclides, we found that many practical direct labeling methodologies have been developed to incorporate radionuclides into the MNP core without using extra reagents, including chemisorption, radiochemical doping, hadronic bombardment, encapsulation, and isotope or cation exchange. From the perspective of practical use, a few relevant examples are presented and discussed in terms of their pros and cons. We further reviewed the determinants of in vivo pharmacokinetic parameters of MNPs, including factors influencing their in vivo absorption, distribution, metabolism, and elimination, and discussed the challenges and opportunities in the development of radiolabeled MNPs for in vivo biomedical applications. Taken together, we believe the cumulative advancement summarized in this review would provide a general guidance in the field for design and synthesis of radiolabeled MNPs towards practical realization of their much desired theranostic capabilities. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > Diagnostic Nanodevices Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Current outlook on radionuclide delivery systems: from design consideration to translation into clinics

Cited by 66 publications

References 245 publications

Gold Nanoparticles Permit In Situ Absorbed Dose Evaluation in Boron Neutron Capture Therapy for Malignant Tumors

Gold Nanoparticles Permit In Situ Absorbed Dose Evaluation in Boron Neutron Capture Therapy for Malignant Tumors

Nanomaterials for cancer therapy: current progress and perspectives

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Contact Info

Product

Resources

About